Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

APL-102

Other · developed by Apollomics

Phase 1 Most advanced trial (none active)
APLM Developer
1 Registered trials

What is APL-102?

APL-102 is an investigational agent studied in patients with advanced solid tumors, with dose escalation and extension cohorts planned to evaluate safety and antitumor activity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
No other name so far
Drug type
Other
Therapy area
Oncology
Developer
Apollomics Inc. (APLM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05055518 Phase 1 Advanced Solid Tumor Suspended APLM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

More from Apollomics

Vebreltinib Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the APLM page.

Follow APLM, the company behind APL-102

See APLM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APLM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.